Affimed NV
AFMD0.181USD
-0.098-34.95%
收盤 08/04, 16:00（美東）報價延遲15分鐘
2.98M總市值
虧損本益比TTM
關於 Affimed NV 公司
Affimed NV 是一家臨牀階段的生物製藥公司，專注於發現和開發癌症免疫療法。該公司的候選產品是在免疫腫瘤學領域開發的，免疫腫瘤學代表了一種癌症研究方法，旨在利用人體自身的免疫系統對抗腫瘤細胞。其產品線包括 AFM13、AFM13 + 過繼性 NK 細胞、AFM13 + 抗 PD-1、AMF24、AMF26、AMF28 和 AMF32。該公司正在招募患者參加 AFM13 的註冊導向研究，用於治療 CD30 陽性復發/難治性外周 T 細胞淋巴瘤，以及 AFM24 的 1/2a 期劑量遞增/擴展研究，用於治療晚期 EGFR 表達實體瘤。其臨牀前候選產品包括用於治療多發性骨髓瘤的 AMF26，以及用於治療多種腫瘤靶點的 AMF28 和 AMF32。此外，該公司還與 Genentech 合作開發和商業化用於治療多種癌症的某些候選產品。
公司簡介
公司代碼AFMD
公司名稱Affimed NV
上市日期Sep 12, 2014
CEOMr. Shawn M. Leland
員工數量76
證券類型Ordinary Share
年結日Sep 12
公司地址Im Neuenheimer Feld 582
城市HEIDELBERG
上市交易所Berne Stock Exchange
國家Germany
郵編69120
電話49621560030
網址https://www.affimed.com/
公司代碼AFMD
上市日期Sep 12, 2014
CEOMr. Shawn M. Leland
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Ms. Uta Kemmerich-Keil
Ms. Uta Kemmerich-Keil
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
11.00K
+83.33%
Mr. Shawn M. Leland
Mr. Shawn M. Leland
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Bernhard R. M. Ehmer
Dr. Bernhard R. M. Ehmer
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Thomas Hecht, M.D.
Dr. Thomas Hecht, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
收入明細
單位: EUR更新時間: 7月6日 週日
單位: EUR更新時間: 7月6日 週日
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務EUR
名稱
營收
佔比
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
地區EUR
名稱
營收
佔比
United States
155.00K
100.00%
Germany
0.00
0.00%
業務
地區
業務EUR
名稱
營收
佔比
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
股東統計
更新時間: 7月25日 週五
更新時間: 7月25日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
持股股東
持股股東
佔比
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
股東類型
持股股東
佔比
Venture Capital
8.49%
Hedge Fund
7.52%
Individual Investor
6.01%
Investment Advisor/Hedge Fund
1.57%
Investment Advisor
1.14%
Research Firm
0.79%
Other
74.48%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
144
3.89M
25.52%
-2.82M
2025Q1
194
5.44M
35.72%
-1.40M
2024Q4
223
4.37M
28.70%
-3.86M
2024Q3
244
6.36M
129.59%
-2.88M
2024Q2
256
6.34M
129.44%
-2.70M
2024Q1
265
6.05M
127.57%
-3.49M
2023Q4
282
6.20M
128.84%
-3.49M
2023Q3
294
6.99M
46.94%
-2.84M
2023Q2
315
7.55M
50.71%
-3.53M
2023Q1
317
8.81M
59.15%
-2.41M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Gilde Healthcare Partners B.V.
812.50K
5.34%
+812.50K
--
Mar 15, 2024
683 Capital Management LLC
654.60K
4.3%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
442.65K
2.91%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
342.86K
2.25%
--
--
Mar 31, 2025
Hoess (Adi Ph.D.)
319.68K
2.1%
+66.08K
+26.06%
Mar 15, 2024
Tang Capital Management, LLC
148.31K
0.97%
--
--
Mar 31, 2025
Fischer (Wolfgang)
145.54K
0.96%
+37.29K
+34.45%
Mar 15, 2024
The Vanguard Group, Inc.
129.56K
0.85%
--
--
Mar 31, 2025
Intellectus Partners, LLC
126.41K
0.83%
--
--
Mar 31, 2025
Marshall Wace LLP
111.64K
0.73%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
iShares Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
佔比0%
SPDR S&P International Small Cap ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
SPDR Portfolio Developed World ex-US ETF
佔比0%
iShares Biotechnology ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
公告日期
類型
比率
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
